MedTrace Logo

The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer

NCT02687321 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2018-07-26

No results posted yet for this study

Summary

To evaluate and to compare the effectiveness of CA-125 and HE4 serum levels in epithelial ovarian cancer (OC) in follow-up in terms of time to detection of elevation after the end of the first line treatment. To evaluate the lead-time of the rise of marker levels before epithelial OC recurrence diagnosis by Computed tomography (CT) imaging method. To evaluate the appropriate HE4 cut-off value for follow-up of patients after the treatment of ovarian, Fallopian tube and primary peritoneal cancer.

Conditions

  • Ovarian Neoplasms

Interventions

OTHER

Determination of CA 125 and HE4, Computed tomography

Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.

Sponsors & Collaborators

  • University Hospital Pilsen

    collaborator OTHER

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Vit Weinberger, M.D., Ph.D. · University Hospital Brno

  • Jiri Presl, M.D., Ph.D. · University Hospital Pilsen

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Czechia
  • Hungary
  • Poland
  • Slovakia
  • Spain
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687321 on ClinicalTrials.gov